TACE patient selection and tumor response assessment — the increasingly sophisticated frameworks for selecting optimal TACE candidates, predicting response, and monitoring post-TACE tumor response using imaging biomarkers and clinical assessment tools — represent important clinical market developments that guide procedural decision-making, with the Transarterial Chemoembolization Market reflecting patient selection science as a quality improvement market dimension.

ART score for TACE retreatment decisions — the Assessment for Retreatment with TACE (ART) score incorporating tumor response (modified RECIST criteria) and liver function changes after initial TACE to guide retreatment decisions — represents the evidence-based TACE retreatment selection tool. The ART score's validation demonstrating that patients with ART score zero to one-point-five (good tumor response, stable liver function) benefit from retreatment while ART score three or greater (poor response, liver function deterioration) do not benefit from further TACE creates the clinical selection framework for optimizing TACE repeat procedures.

Modified RECIST for HCC treatment response — the specific response assessment criteria for locoregional HCC therapies measuring viable tumor enhancement (arterial enhancement) rather than total tumor size — creates the appropriate imaging biomarker for TACE response assessment. Complete response (CR) by mRECIST (no arterial enhancement), partial response (PR — greater than thirty percent reduction in arterial enhancement), progressive disease, and stable disease represent the response categories that guide subsequent treatment decisions after TACE.

Tumor markers and TACE response — the role of AFP (alpha-fetoprotein), PIVKA-II (des-gamma-carboxyprothrombin), and emerging liquid biopsy markers (circulating tumor DNA, circulating tumor cells) in monitoring TACE treatment response and predicting recurrence — represents the biomarker adjunct to imaging assessment. AFP kinetics after TACE providing prognostic information complementing imaging response creates the multiparametric response assessment framework for comprehensive TACE monitoring.

Do you think the development of predictive biomarkers for TACE response will eventually enable meaningful patient stratification that improves TACE clinical outcomes by identifying which intermediate HCC patients will respond versus those who should receive alternative treatments upfront?

FAQ

What is the ART score and how does it guide TACE retreatment? ART (Assessment for Retreatment with TACE) score: Development: Sieghart et al. (Vienna Medical University); Post-treatment assessment after first TACE; Scoring components: Radiological response (mRECIST): complete/partial response (zero points); stable disease (one point); progressive disease (three points); Increase in Child-Pugh score: no increase (zero points); increase of one point (one point); increase two or more points (two points); AST increase (optional component in some scoring versions); Total score range: zero to five; Interpretation: ART zero to one-point-five: good candidates for retreatment; ART two to two-point-five: intermediate; individualize decision; ART three or greater: poor candidates; retreatment rarely beneficial; consider alternative treatments (systemic therapy, SIRT); Validation: original validation cohort and multiple international validation studies confirming prognostic value; prospective randomized ARTEST trial evaluating ART score-guided versus standard retreatment; AASLD and EASL guidelines acknowledge ART score in retreatment decision framework; practice: performed at four to six week post-TACE follow-up CT/MRI; guides MDT discussion about second TACE versus systemic treatment transition.

What imaging criteria are used to assess TACE response? TACE response assessment by imaging: Modified RECIST (mRECIST) for HCC: measures viable tumor (arterial enhancement) rather than total tumor size; standard WHO RECIST measures all tumor tissue including necrotic areas; HCC-specific: viable tumor defined as arterial phase enhancement; non-enhancing regions (necrosis) not counted; measurement: longest diameter of enhancing viable tumor; CR: no arterial enhancement in all target lesions; PR: at least thirty percent decrease in sum of viable target lesion diameters; PD: at least twenty percent increase in viable tumor; SD: neither PR nor PD; LI-RADS criteria: liver imaging reporting and data system for HCC assessment; viable HCC categories after treatment (LI-RADS treated observation scoring); response categories from viable to complete necrosis; EASL criteria: similar concept to mRECIST; measures percentage necrosis; RECICL (Japanese): modified criteria for Japan; European guidelines: EASL guidelines recommend mRECIST or RECICL; American guidelines (AASLD): mRECIST preferred; timing: imaging at four to eight weeks after TACE; routine follow-up every three months; earlier if clinical concern.

#TACE #ARTscore #mRECISTHCC #TACEresponse #HCCimaging #TACEassessment